ArticleJournal of the American Heart Association2026
Regulating the Impact of Hypertension on Stroke: Therapeutic Potential of a Peptide Mimetic of Tyrosine Phosphatase STEP.
Article in Journal of the American Heart Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundIn spite of the advances in understanding the pathophysiology of stroke, successful treatment remains a major challenge. The lack of consideration of preclinical studies with associated comorbidities is a primary factor for the translational failure, as ~94% of patients with stroke have ≥1 preexisting comorbidities. Because hypertension is the most common comorbid condition in patients with stroke and predisposition to hypertension is known to worsen stroke outcome, we evaluated the efficacy of a novel neuroprotective peptide derived from the brain-enriched and neuron-specific tyrosine phosphatase striatal enriched phosphatase (STEP) in attenuating ischemic brain damage under hypertensive conditions.
methodsMild ischemic insult was induced in hypertensive rats by middle cerebral artery occlusion for 60 minutes followed by reperfusion for 30 days. In a subset of hypertensive rats, the STEP-mimetic peptide (STEP-peptide) was administered intravenously 6 hours after the onset of the insult. Magnetic resonance imaging scans of the brain were done 1, 7, and 28 days after the insult to assess temporal evolution of ischemic brain damage. Behavioral studies were performed weekly starting 7 days after the onset of the insult. Histopathological staining of brain sections was done 30 days later.
resultsThe results show that delayed treatment with a single intravenous administration of the STEP-peptide 6 hours after the onset of the insult reduces mortality rate. In the surviving rats, T2-weighted imaging, and diffusion tensor imaging of the brain on post-stroke days 1, 7, and 28 show significant reduction in infarct size and improvement of structural integrity within the infarcted area following treatment. Furthermore, behavioral studies show significant improvement in motor coordination, sensory motor function, and spatial memory over time.
conclusionsThe efficacy of the novel STEP-peptide in mitigating brain damage and improving functional recovery in a preclinical stroke model of hypertension holds promise for the development of potential strategies to treat acute ischemic stroke in the population with hypertension.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.